Literature DB >> 21570677

Lewis X oligosaccharides-heparanase complex targeting to DCs enhance antitumor response in mice.

Hongjie Chen1, Bangqing Yuan, Zhaocong Zheng, Zheng Liu, Shousen Wang.   

Abstract

Heparanase has been proved as an promising tumor antigen for the therapeutical target. However, the antigen alone cannot fully elicit the immune response in vivo. In this study, Lewis X oligosaccharides-heparanase complex was prepared, which can target to the dendritic cells (DCs) via dendritic cell-specific intercellular-adhesion-molecule-grabbing non-integrin (DC-SIGN). In addition, the DCs were loaded with the complex, and then were utilized to immunize mice to detect the immune response. Our data demonstrated that the modified DCs could enhance the specific IFN-γ production and cytotoxic T cell response. Furthermore, the modified DCs could also significantly suppress the established tumor growth and prolong the life span of tumor-bearing mice. Therefore, the Lewis X oligosaccharides-heparanase complex might be regarded as an ideal vaccine, and represent a novel way for the therapeutical strategy of tumor. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570677     DOI: 10.1016/j.cellimm.2011.03.021

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Dendritic cell targeted vaccines: Recent progresses and challenges.

Authors:  Pengfei Chen; Xinsheng Liu; Yuefeng Sun; Peng Zhou; Yonglu Wang; Yongguang Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Immunomodulatory glycan lacto-N-fucopentaose III requires clathrin-mediated endocytosis to induce alternative activation of antigen-presenting cells.

Authors:  Leena Srivastava; Smanla Tundup; Beak-San Choi; Thomas Norberg; Donald Harn
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

3.  Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival.

Authors:  Martín E Rabassa; Adrian Pereyra; Liliana Pereyra; Amada Segal-Eiras; Martín C Abba; Maria V Croce
Journal:  Pathol Oncol Res       Date:  2017-07-05       Impact factor: 3.201

Review 4.  Targeting C-Type Lectin Receptors for Cancer Immunity.

Authors:  Huimin Yan; Tomomori Kamiya; Papawee Suabjakyong; Noriko M Tsuji
Journal:  Front Immunol       Date:  2015-08-24       Impact factor: 7.561

Review 5.  Targeting antigens to dendritic cell receptors for vaccine development.

Authors:  Vasso Apostolopoulos; Theresia Thalhammer; Andreas G Tzakos; Lily Stojanovska
Journal:  J Drug Deliv       Date:  2013-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.